Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells

Aims Familial hypertrophic cardiomyopathy (HCM) is one the most common heart disorders, with gene mutations in the cardiac sarcomere. Studying HCM with patient-specific induced pluripotent stem-cell (iPSC)-derived cardiomyocytes (CMs) would benefit the understanding of HCM mechanism, as well as the development of personalized therapeutic strategies. Methods and results To investigate the molecular mechanism underlying the abnormal CM functions in HCM, we derived iPSCs from an HCM patient with a single missense mutation (Arginine442Glycine) in the MYH7 gene. CMs were next enriched from HCM and healthy iPSCs, followed with whole transcriptome sequencing and pathway enrichment analysis. A widespread increase of genes responsible for ‘Cell Proliferation’ was observed in HCM iPSC-CMs when compared with control iPSC-CMs. Additionally, HCM iPSC-CMs exhibited disorganized sarcomeres and electrophysiological irregularities. Furthermore, disease phenotypes of HCM iPSC-CMs were attenuated with pharmaceutical treatments. Conclusion Overall, this study explored the possible patient-specific and mutation-specific disease mechanism of HCM, and demonstrates the potential of using HCM iPSC-CMs for future development of therapeutic strategies. Additionally, the whole methodology established in this study could be utilized to study mechanisms of other human-inherited heart diseases.

[1]  Craig T. January,et al.  Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.

[2]  H. Chiao,et al.  Contraction-induced cell wounding and release of fibroblast growth factor in heart. , 1995, Circulation research.

[3]  P. Kirchhof,et al.  Familial Hypertrophic Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced Ventricular Tachycardia and Ca2+-Dependent Action Potential Remodeling , 2003, Circulation research.

[4]  Eric D. Adler,et al.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.

[5]  S. Vatner.  FGF induces hypertrophy and angiogenesis in hibernating myocardium. , 2005, Circulation research.

[6]  L. Monserrat,et al.  Mutaciones en el gen de la cadena pesada de la betamiosina en pacientes con miocardiopatía hipertrófica , 2006 .

[7]  Carlos A. Dumont,et al.  [Beta-myosin heavy-chain gene mutations in patients with hypertrophic cardiomyopathy]. , 2006, Revista espanola de cardiologia.

[8]  Shan Xu,et al.  E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway , 2012, Acta Pharmacologica Sinica.

[9]  M. Mattson,et al.  SDF1α/CXCR4 signaling stimulates β-catenin transcriptional activity in rat neural progenitors , 2006, Neuroscience Letters.

[10]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[11]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[12]  A. Marian.  Modifier genes for hypertrophic cardiomyopathy. , 2002, Current opinion in cardiology.

[13]  U. Schotten,et al.  Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase protein expression in compensated primary and secondary human cardiac hypertrophy. , 1999, Journal of molecular and cellular cardiology.

[14]  C. Poggesi,et al.  Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy , 2013, Circulation.

[15]  R. Moon,et al.  Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells , 2007, Proceedings of the National Academy of Sciences.

[16]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[17]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[18]  D. Fatkin,et al.  Molecular mechanisms of inherited cardiomyopathies. , 2002, Physiological reviews.

[19]  P. Armstrong,et al.  Regulation of proliferation of the fetal myocardium , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[20]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[21]  H. Kee,et al.  Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy , 2010, Journal of biomedicine & biotechnology.

[22]  W. Schulz,et al.  E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells , 2003, British Journal of Cancer.

[23]  E. Kardami,et al.  High and low molecular weight fibroblast growth factor-2 increase proliferation of neonatal rat cardiac myocytes but have differential effects on binucleation and nuclear morphology. Evidence for both paracrine and intracrine actions of fibroblast growth factor-2. , 1996, Circulation research.

[24]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[25]  G. Salama,et al.  High-purity enrichment of functional cardiovascular cells from human iPS cells. , 2012, Cardiovascular research.

[26]  E. Keung,et al.  Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. , 1989, Circulation research.

[27]  D. Kaye,et al.  Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. , 1996, The Journal of clinical investigation.

[28]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[29]  Jianqun Lu,et al.  CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[30]  G. Tomaselli,et al.  Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.

[31]  H. Izawa,et al.  Reduced Myocardial Sarcoplasmic Reticulum Ca2+-ATPase mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy , 2001, Circulation.

[32]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[33]  David M. Warshaw,et al.  Understanding Cardiomyopathy Phenotypes Based on the Functional Impact of Mutations in the Myosin Motor , 2012, Circulation research.

[34]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[35]  J. Partanen,et al.  Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. , 2005, Developmental cell.

[36]  I. Komuro,et al.  Developmental stage-specific biphasic roles of Wnt/β-catenin signaling in cardiomyogenesis and hematopoiesis , 2006, Proceedings of the National Academy of Sciences.

[37]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[38]  T. McKinsey.  The biology and therapeutic implications of HDACs in the heart. , 2011, Handbook of experimental pharmacology.

[39]  Christine E Seidman,et al.  The genetic basis for cardiac remodeling. , 2005, Annual review of genomics and human genetics.

[40]  H. Izawa,et al.  mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy , 2001 .

[41]  T. McKinsey.  Therapeutic potential for HDAC inhibitors in the heart. , 2012, Annual review of pharmacology and toxicology.

[42]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[43]  A. Marian,et al.  The molecular genetic basis for hypertrophic cardiomyopathy. , 2001, Journal of molecular and cellular cardiology.

[44]  D. Bers.  Calcium cycling and signaling in cardiac myocytes. , 2008, Annual review of physiology.

[45]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[46]  W. Catterall.  Structure and regulation of voltage-gated Ca2+ channels. , 2000, Annual review of cell and developmental biology.

[47]  M. Mattson,et al.  SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. , 2006, Neuroscience letters.

[48]  H. Katus,et al.  Mechanisms of disease: hypertrophic cardiomyopathy , 2012, Nature Reviews Cardiology.

[49]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[50]  M. Bergmann.  WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. , 2010, Circulation research.

[51]  E. Rubin,et al.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.